Mandate

Vinge has advised Autoliv and Veoneer

Vinge has advised Autoliv, Inc. (“Autoliv”) and Veoneer, Inc. (“Veoneer”) in connection with the spin-off and listing of Veoneer on the New York Stock Exchange and Nasdaq Stockholm. First day of regular trading of Veoneer was July 2, 2018.

On December 12, 2017, Autoliv announced that, following the conclusion of a strategic review by the board of directors, it intended to spin-off its Electronics business segment, creating a new, independent publicly traded company called Veoneer, Inc. To implement the spin-off, Autoliv has transferred the Electronics business to Veoneer and its subsidiaries and has distributed 100% of the outstanding shares of common stock of Veoneer on a pro rata basis to existing holders of common shares of Autoliv, including shares represented by Swedish Depository Receipts (“SDRs”). In connection with the spin-off and the listing of shares of Veoneer common stock on the New York Stock Exchange and Veoneer SDRs on Nasdaq Stockholm, Autoliv and Veoneer have prepared a registration statement as well as a Swedish prospectus. The registration statement became effective and the prospectus was approved and registered on June 8, and the first day of regular way trading of Veoneer was July 2, 2018.

Veoneer is a growing technology company, focused on active safety, ADAS, autonomous driving and automotive safety electronics. Veoneer’s purpose is to create trust in mobility.  In 2017, Veoneer (as the Electronics business segment of Autoliv) had a turnover of $2.3 billion. Veoneer currently has around 7,600 associates out of which roughly half are in RD&E. Veoneer’s customers are nearly all the top automotive manufacturers in the world. The market value of Veoneer, Inc. on the first day of trading was approximately SEK 34 billion.

Vinge’s team primarily consisted of Göran Nyström, Dain Hård Nevonen, Malte Hedlund, Sabina Kihlberg and Stephanie Stiernstedt, as well as Albert Wållgren, Helena Håkansson, Lionardo Ojeda and Sara Osman regarding financing issues.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025